Convalescent Plasma for Hospitalized COVID-19 Patients : A Single-Center Experience
In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80−320). Their median age was 68 years (IQR, 56−78 years), and 62% were males. At enrollment, 55% of patients had an increased body mass index (BMI), and 25.6% had at least three comorbidities. The 28-day crude mortality rate was 12.6% (51/405). Young age (<68 years), mild disease (admission to low-intensity departments) and early treatment (<7 days from symptoms onset) with high nAb titer (≥320) CCP were found as independently associated with a favorable response to CCP treatment. No safety concerns were recorded, with a rate of CCP-related adverse reactions (all of mild intensity) of 1.3%. In our real-life experience, the first in the western world, early administration of high-titer CCP was a safe and effective treatment for hospitalized COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Life (Basel, Switzerland) - 12(2022), 3 vom: 14. März |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/life12030420 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338604588 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338604588 | ||
| 003 | DE-627 | ||
| 005 | 20231226001039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/life12030420 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1128.xml |
| 035 | |a (DE-627)NLM338604588 | ||
| 035 | |a (NLM)35330170 | ||
| 035 | |a (PII)420 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franchini, Massimo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Convalescent Plasma for Hospitalized COVID-19 Patients |b A Single-Center Experience |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80−320). Their median age was 68 years (IQR, 56−78 years), and 62% were males. At enrollment, 55% of patients had an increased body mass index (BMI), and 25.6% had at least three comorbidities. The 28-day crude mortality rate was 12.6% (51/405). Young age (<68 years), mild disease (admission to low-intensity departments) and early treatment (<7 days from symptoms onset) with high nAb titer (≥320) CCP were found as independently associated with a favorable response to CCP treatment. No safety concerns were recorded, with a rate of CCP-related adverse reactions (all of mild intensity) of 1.3%. In our real-life experience, the first in the western world, early administration of high-titer CCP was a safe and effective treatment for hospitalized COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a convalescent plasma | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a safety | |
| 700 | 1 | |a Glingani, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Donno, Giuseppe De |e verfasserin |4 aut | |
| 700 | 1 | |a Lucchini, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Beccaria, Massimiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Amato, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Castelli, Gian Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Bianciardi, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Pagani, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Ghirardini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Puma, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Presciuttini, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Costantino, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Frigato, Marilena |e verfasserin |4 aut | |
| 700 | 1 | |a Crosato, Verena |e verfasserin |4 aut | |
| 700 | 1 | |a Tiecco, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Mulè, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Papalia, Dorothea Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Inglese, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Spreafico, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Garuti, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Pecoriello, Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Cervi, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Greco, Graziana |e verfasserin |4 aut | |
| 700 | 1 | |a Galavotti, Vanni |e verfasserin |4 aut | |
| 700 | 1 | |a Santini, Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Berselli, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Montalto, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoletti, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Bellometti, Simona Aurelia |e verfasserin |4 aut | |
| 700 | 1 | |a Capuzzo, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Benazzi, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Grisolia, Gianpaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Pajola, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Stradoni, Raffaello |e verfasserin |4 aut | |
| 700 | 1 | |a Zani, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Verzola, Adriano |e verfasserin |4 aut | |
| 700 | 1 | |a Codeluppi, Vito |e verfasserin |4 aut | |
| 700 | 1 | |a Vesentini, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Bellocchio, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Candini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ambrosi, Giorgina |e verfasserin |4 aut | |
| 700 | 1 | |a Carandina, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Scarduelli, Cleante |e verfasserin |4 aut | |
| 700 | 1 | |a Reggiani, Albino |e verfasserin |4 aut | |
| 700 | 1 | |a Casari, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a On Behalf Of Convalescent Plasma Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life (Basel, Switzerland) |d 2011 |g 12(2022), 3 vom: 14. März |w (DE-627)NLM243284799 |x 2075-1729 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:3 |g day:14 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/life12030420 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 3 |b 14 |c 03 | ||